The drug people have been searching for as a "pancreatic cancer pill" is Rasonque, the brand name for daraxonrasib, an oral RAS inhibitor the U.S. Food and Drug Administration approved on Aug. 26, 2026, for a tightly defined group of adults with advanced disease. It is a once-daily tablet, not a first-line therapy for every new diagnosis, and it is not a claimed cure.
The FDA approved Rasonque for adults with metastatic pancreatic adenocarcinoma who have already received at least one prior systemic therapy, or who are not candidates for multi-agent systemic therapy. Pancreatic adenocarcinoma, which starts in cells lining the ducts of the pancreas, accounts for about 90 to 95 percent of the 67,000 new pancreatic cancer cases diagnosed in the United States each year, the agency said, citing the National Cancer Institute. It is roughly 3.2 percent of all cancer diagnoses but a much larger share of cancer deaths, the FDA noted, because it is often found late and has had few targeted options.
In a randomized, open-label, multicenter trial of 500 adults with previously treated metastatic pancreatic adenocarcinoma, median overall survival was 13.2 months with Rasonque versus 6.7 months with standard chemotherapy, the FDA said. Acting Commissioner Kyle Diamantas called it "a critical new option for patients facing an extraordinarily difficult and historically hard-to-treat cancer." Angelo de Claro, director of the FDA's Oncology Center of Excellence, said the drug "showed unprecedented results in an area of high unmet need," and that the approval came 6.5 months before the user fee deadline.
The agency granted Breakthrough Therapy, Orphan Drug, and Priority Review designations and reviewed the application under the Commissioner's National Priority Voucher pilot. In May, it issued a "safe to proceed" letter for an expanded-access protocol so some patients could receive the then-investigational drug before approval. The approval went to Revolution Medicines, Inc.
The most common side effects listed by the FDA are rash, diarrhea, stomatitis, nausea, fatigue, vomiting, abdominal pain, edema, decreased appetite, and hemorrhage. Those are the official safety findings, not a complete substitute for a prescribing label or a conversation with an oncologist. The approval does not mean Rasonque is appropriate for people who have not had prior treatment, or who have a different kind of pancreatic tumor, and later trial results can still change how doctors use it. Anyone who saw a headline about a new pancreatic cancer pill should start with the FDA's actual indication, the survival figures from that 500-person trial, and the side-effect list, not with unverified social posts.
